Rhythm Pharmaceuticals

Boston, United States Founded: 2010 • Age: 16 yrs Listed
Developer of peptide therapeutics for the treatment of rare genetic deficiencies

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a publicly listed company based in Boston (United States) founded in 2010. Rhythm Pharmaceuticals has raised $84 million across 9 funding rounds from investors including HHS, Ipsen and Orbimed. The company has 283 employees. Rhythm Pharmaceuticals has completed 1 acquisition, including Xinvento. Its chief executive, as recorded, is David Meeker. Its website rhythmtx.com draws about 31 thousand monthly visits. Rhythm Pharmaceuticals offers products and services including IMCIVREE and Clinical Trials. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Rare Diseases. Its legal entity is Rhythm Pharmaceuticals, Inc.

Company details

Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.

  • Headquarters Boston, United States
  • Employees 283
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Website motustx.com
  • Social LinkedIn X
  • Legal Name Rhythm Pharmaceuticals, Inc.
Key Metrics
  • Annual Revenue
    $189.76 M (USD)
    45.83
    as on Dec 31, 2025
  • Net Profit
    -$196.54 M (USD)
    24.58
    as on Dec 31, 2025
  • EBITDA
    -$190.68 M (USD)
    27.76
    as on Dec 31, 2025
  • Total Equity Funding
    $84M (USD)

    in 9 rounds

  • Latest Funding Round
    $150M (USD), Post-IPO

    Apr 2024

  • Investors
    HHS

    & 9 more

  • Employee Count
    283
  • Investments & Acquisitions

Products & Services of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals offers a comprehensive portfolio of products and services, including IMCIVREE and Clinical Trials.

IMCIVREE
Biopharmaceuticals

IMCIVREE is utilized as a treatment for rare obesity disorders associated with neuroendocrine diseases

Clinical Trials
Research Services

Clinical trials are conducted by Rhythm Pharmaceuticals to advance treatments for hyperphagia and obesity

Funding Insights of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals has successfully raised a total of $84M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $84M
  • Total Rounds 9
  • Last Round Post-IPO — $150M
  • First Round $21M

    (Mar 2010)

  • Investors Count 10

All 9 funding rounds of Rhythm Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2024$150MPost-IPO––
Feb 2017$41MDebt – Venture––
Jul 2015$999,353Grant––
Sep 2013$1.4MGrant––
Jul 2013$11MSeries B––
–
Dec 2012$25MSeries B––
Nov 2012$8MSeries B–Pfizer Venture Investments
Aug 2010$19MSeries A–Third Rock Ventures
Mar 2010$21MSeries A––
Valuation history

10 investors in total: 10 institutional.

Investors in Rhythm Pharmaceuticals

Rhythm Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Ipsen and Orbimed.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Health-tech companies are targeted for venture capital investments.
1999perceptivelife.comNew York, United States
Healthcare ecosystem is supported through investment and innovation by Deerfield.
deerfield.comNew York, United States
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
1989orbimed.comNew York, United States
Venture capital investments are offered to startups by NEA.
nea.comMenlo Park, United States
Venture capital is focused on healthcare by Pfizer's investment arm.
pfizer.com/partnering/areas_of_interest/venture_investmentsNew York, United States
Venture capital funding is provided to early-stage life science companies.
thirdrockventures.comBoston, United States
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
1929ipsen.com
Invests in biotech firms developing life-saving drugs and technologies.
mpmcapital.com
Public health and human services are overseen by HHS.
1953hhs.gov
Research for Parkinson's disease is funded by the foundation.
2000michaeljfox.orgNew York, United States
Premium access

Investor details for Rhythm Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Rhythm Pharmaceuticals

83 people are tracked at Rhythm Pharmaceuticals (54 in leadership, 7 in board & advisors, 22 in team); the tracked headcount is 283.

NameRoleGroup
David Meeker
CEOLeadership
Job Den Hollander
Senior Director International MarketingLeadership
Jieruo Liu
Director, Value & EvidenceLeadership
Yann Mazabraud
EVP, Head of InternationalLeadership
Pam Cramer
Chief Human Resource OfficerLeadership
Jennifer Chien
EVP, Head of North AmericaLeadership
Jodi Dreiling
Director Of Medical EducationLeadership
Ann Hnatishion
Vice President, US SalesLeadership
Shelina Jiwa
Marketing DirectorLeadership
Vito Lavopa
Head - Drug Substance, Technical OperationsLeadership
Camilo R.
Vice President Market Access And External AffairsLeadership
Hunter Smith
CFOLeadership
Michalis Douramanis
IT CRM Business Support Partner, InternationalLeadership
Andy Sontag
Vice President, Head Of Information TechnologyLeadership
Gauri Malthankar
Senior Medical Director, North AmericaLeadership
Ali Mohamadi
Vice President, Head Of Medical Affairs North AmericaLeadership
Lisa Burke
Executive Director, Global Medical AffairsLeadership
Ilana Koyfman
Director, Head Of Medical InformationLeadership
Laura Katz
Senior National Director, Field MedicalLeadership
Cory Vick Baker
Associate Director, Field Medical And Field-based TrainerLeadership

63 more people are available in the full profile.

Premium access

Complete people profiles for Rhythm Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol RYTM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Oct 2017
  • Listed onNASDAQ: RYTM
  • Listed entityRhythm Pharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINUS76243J1051
  • Share price$86.61 (-3.57% on the day) · 2026-10-13
  • Market capitalisation$5.96B
  • EPS (diluted, trailing year)$-3.12
  • Volume (last session)623,190

Financials of Rhythm Pharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$189.8M-$196.5M-$190.7M
2024$130.1M-$260.6M-$263.9M
2023$77.4M-$184.7M-$182.6M
2022$23.6M-$181.1M-$177.8M
2021$3.1M-$69.6M-$168.9M
Premium access

Detailed financial statements for Rhythm Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Rhythm Pharmaceuticals

Rhythm Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xinvento.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Therapies for congenital hyperinsulinism are researched and developed.
xinvento.comAmsterdam, Netherlands2021Feb 2023••••
Premium access

Complete acquisition details for Rhythm Pharmaceuticals

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Rhythm Pharmaceuticals

5 dated milestones of Rhythm Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.

  1. Founded Rhythm Pharmaceuticals is founded.
  2. Funding First funding round of $21.0M.
  3. IPO Lists on the stock exchange (IPO).
  4. Acquisition Acquires Xinvento.
  5. Funding Latest funding round, Post-IPO, of $150.0M.

Web traffic of Rhythm Pharmaceuticals

The website of Rhythm Pharmaceuticals (rhythmtx.com) receives about 30.7K visits a month and ranks #1,305,357 among all websites worldwide, #1,678 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    30.7K

    ▲ 50.3% vs previous month

  • Unique visitors
    7.5K

    per month

  • Global rank
    #1,305,357

    among all websites

  • Category rank
    #1,678

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Rhythm Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
avadel.com
100%
8K#1,705,741View details
rythm.com
rythm.com
63%
#611,361–
endocrine-abstracts.org
endocrine-abstracts.org
54%
#398,762–

Top companies in Metabolic Diseases

3 companies that operate in the same segment as Rhythm Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Developer of cortisol modulators for the treatment of various diseases
1998Menlo Park, California, United StatesUSD 761.41 M500
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Rhythm Pharmaceuticals

Premium access

Complete news archive for Rhythm Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rhythm Pharmaceuticals

Rhythm Pharmaceuticals was founded in 2010.

Rhythm Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

David Meeker is the CEO of Rhythm Pharmaceuticals, as recorded in our data.

Rhythm Pharmaceuticals is a funded company, having raised a total of $84M across 9 funding rounds to date. The company's 1st funding round was a Series A of $21M, raised on Mar 2010.

Rhythm Pharmaceuticals has 283 employees.

Annual revenue of Rhythm Pharmaceuticals is $189.76M as on Dec 31, 2025.

Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.

Rhythm Pharmaceuticals offers IMCIVREE and Clinical Trials.

Yes, Rhythm Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol RYTM.

Rhythm Pharmaceuticals has made 1 acquisition, including Xinvento.

Rhythm Pharmaceuticals has 10 investors. Key investors include HHS, Ipsen, Orbimed, The Michael J. Fox Foundation, and Perceptive Advisors.

Rhythm Pharmaceuticals operates through Rhythm Pharmaceuticals, Inc.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available